lobemizole

Lobemizole (Y-3) is a small molecule innovative drug candidate developed by Kangzhe Pharmaceutical for the treatment of acute ischemic stroke (AIS). It acts as a potent and selective inhibitor of acid-sensing ion channel 1a (ASIC1a). During an ischemic stroke, the resulting acidosis activates ASIC1a, leading to calcium overload and subsequent neuronal death; by inhibiting these channels, lobemizole provides neuroprotection and reduces infarct volume. The drug is administered via intravenous injection and is currently in Phase 2 clinical trials in China. It is recognized as a Class 1 innovative drug, representing a novel approach to stroke therapy by targeting the underlying mechanisms of acidotoxicity.

Other names

注射用洛贝米柳Lobemizole for injection